CLDX Q1 2017 Earnings — Celldex Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CLDXCelldex Therapeutics, Inc.

$2B

Q1 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M+17.7% YoY

Gross Profit

-$24M-1581.4% margin

Operating Income

-$35M-2288.9% margin

Net Income

-$34M-2233.4% margin

EPS (Diluted)

$-4.19

QoQ Revenue Growth

-18.1%

Cash Flow

Operating Cash Flow

-$35M

Free Cash Flow

-$36M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$360M

Total Liabilities

$112M

Stockholders' Equity

$248M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$1M	+17.7%
Gross Profit	-$24M	-$50M	+51.5%
Operating Income	-$35M	-$36M	+1.7%
Net Income	-$34M	-$35M	+1.2%